Actively Recruiting
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Led by University of Arkansas, Fayetteville · Updated on 2025-04-02
76
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
CONDITIONS
Official Title
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 18 and 55-years-old.
- Body Mass Index (BMI) between 18 and 35 kg/m2.
- Score of 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
- Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
- Willing to abstain from cannabis or any THC-containing products during the study.
- Have never used synthetic cannabinoids or cannabinoid analogues.
- Willing to maintain a stable treatment regimen with no changes in current medications during the study.
- Not currently taking or prescribed ADHD medication in the past six months.
- Not currently having thoughts of suicide.
- Willing to use effective contraception for 30 days before and after the study (if applicable).
- Access to transportation to the University of Arkansas campus for research visits.
- Willing to follow University COVID-19 safety protocols during the study.
You will not qualify if you...
- Pregnant or breastfeeding.
- History of significant allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
- Use of CBG or other cannabinoid products within 30 days before screening.
- Exposure to investigational drugs or devices within 30 days prior to screening or plans to take them during the study.
- History of bipolar disorder, psychosis, severe major depressive disorder, or substance use disorder.
- Acute illness or currently taking medication for an acute illness.
- History of liver disease or significantly impaired liver function.
- Serious or unstable physical health conditions including neurological, renal, or cardiovascular diseases.
- Atrial fibrillation, bradycardia, or tachycardia detected during study visit.
- Recent illicit drug use other than cannabis or alcohol use within 12 hours before the study visit.
- Currently prescribed or taking medications such as warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, St. John's wort, Epidiolex, escitalopram, cardiovascular medications, or strong CYP3A4 inhibitors.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Arkansas
Fayetteville, Arkansas, United States, 72703
Actively Recruiting
Research Team
E
Ellen W Leen-Feldner, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here